Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight

Norihiro Sato, Shiro Kohi, Keiji Hirata, Michael S Goggins

Research output: Contribution to journalArticle

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains the most deadly disease worldwide, with the lowest survival rate among all cancer types. Recent evidence suggests that hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma is typically characterized by a dense desmoplastic stroma containing a large amount of HA. Accumulation of HA promotes tumor growth in mice and correlates with poor prognosis in patients with PDAC. Because HA is involved in various malignant behaviors of cancer (such as increased cell proliferation, migration, invasion, angiogenesis, and chemoresistance), inhibiting HA synthesis/signaling or depleting HA in tumor stroma could represent a promising therapeutic strategy against PDAC. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA.

Original languageEnglish (US)
JournalCancer Science
DOIs
StateAccepted/In press - 2016

Fingerprint

Hyaluronic Acid
Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Neoplasms
Tumor Microenvironment
Cell Movement
Survival Rate
Cell Proliferation
Growth

Keywords

  • Desmoplasia
  • Hyaluronan
  • Pancreatic ductal adenocarcinoma
  • Tumor stroma
  • Tumor-stroma interaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of hyaluronan in pancreatic cancer biology and therapy : Once again in the spotlight. / Sato, Norihiro; Kohi, Shiro; Hirata, Keiji; Goggins, Michael S.

In: Cancer Science, 2016.

Research output: Contribution to journalArticle

@article{cc9c4fd8b6234f2f88b129a78cf45f04,
title = "Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) remains the most deadly disease worldwide, with the lowest survival rate among all cancer types. Recent evidence suggests that hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma is typically characterized by a dense desmoplastic stroma containing a large amount of HA. Accumulation of HA promotes tumor growth in mice and correlates with poor prognosis in patients with PDAC. Because HA is involved in various malignant behaviors of cancer (such as increased cell proliferation, migration, invasion, angiogenesis, and chemoresistance), inhibiting HA synthesis/signaling or depleting HA in tumor stroma could represent a promising therapeutic strategy against PDAC. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA.",
keywords = "Desmoplasia, Hyaluronan, Pancreatic ductal adenocarcinoma, Tumor stroma, Tumor-stroma interaction",
author = "Norihiro Sato and Shiro Kohi and Keiji Hirata and Goggins, {Michael S}",
year = "2016",
doi = "10.1111/cas.12913",
language = "English (US)",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Role of hyaluronan in pancreatic cancer biology and therapy

T2 - Once again in the spotlight

AU - Sato, Norihiro

AU - Kohi, Shiro

AU - Hirata, Keiji

AU - Goggins, Michael S

PY - 2016

Y1 - 2016

N2 - Pancreatic ductal adenocarcinoma (PDAC) remains the most deadly disease worldwide, with the lowest survival rate among all cancer types. Recent evidence suggests that hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma is typically characterized by a dense desmoplastic stroma containing a large amount of HA. Accumulation of HA promotes tumor growth in mice and correlates with poor prognosis in patients with PDAC. Because HA is involved in various malignant behaviors of cancer (such as increased cell proliferation, migration, invasion, angiogenesis, and chemoresistance), inhibiting HA synthesis/signaling or depleting HA in tumor stroma could represent a promising therapeutic strategy against PDAC. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA.

AB - Pancreatic ductal adenocarcinoma (PDAC) remains the most deadly disease worldwide, with the lowest survival rate among all cancer types. Recent evidence suggests that hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma is typically characterized by a dense desmoplastic stroma containing a large amount of HA. Accumulation of HA promotes tumor growth in mice and correlates with poor prognosis in patients with PDAC. Because HA is involved in various malignant behaviors of cancer (such as increased cell proliferation, migration, invasion, angiogenesis, and chemoresistance), inhibiting HA synthesis/signaling or depleting HA in tumor stroma could represent a promising therapeutic strategy against PDAC. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA.

KW - Desmoplasia

KW - Hyaluronan

KW - Pancreatic ductal adenocarcinoma

KW - Tumor stroma

KW - Tumor-stroma interaction

UR - http://www.scopus.com/inward/record.url?scp=84961185769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961185769&partnerID=8YFLogxK

U2 - 10.1111/cas.12913

DO - 10.1111/cas.12913

M3 - Article

C2 - 26918382

AN - SCOPUS:84961185769

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -